🫀
#ESCCongress 2026 | Cardiovascular Imaging Highlights
What an inspiring few days in Munich!
As EACVI President, it was particularly rewarding to see cardiovascular imaging at the centre of so many discussions — from new evidence and guidelines to artificial intelligence and precision medicine.
One message stood out for me: imaging is moving beyond “what does it look like?” toward “what is the diagnosis, what is the risk, and will this change treatment?”
A few highlights I am taking home:
🔹 CMR + MINOCA — MINOCA remains a working diagnosis. Early CMR is increasingly central to establishing an etiological diagnosis, including infarction, myocarditis and Takotsubo syndrome.
🔹 CMR-GUIDE — Myocardial scar on CMR alone did not identify patients with LVEF 36–50% who benefited from prophylactic ICD implantation — an important reminder that better phenotyping does not always mean more intervention.
🔹 FUSION — Adding FFR-CT after CCTA reduced unnecessary invasive coronary angiography, highlighting the evolution of CT from anatomy toward integrated anatomical and physiological assessment.
🔹 AI plaque quantification — SCAPIS data suggest that automated total coronary plaque volume provides prognostic information beyond traditional risk assessment, CAC and conventional CCTA interpretation.
🔹 CAC-guided prevention — CorCal Outcomes reminds us that better risk phenotyping does not automatically translate into better clinical outcomes.
🔹 AI and quantitative imaging — from automated coronary plaque assessment to AI-supported quantification of mitral regurgitation, AI has the potential to make cardiovascular imaging more reproducible, scalable and clinically meaningful.
🔹 Imaging and stroke prediction — fascinating work exploring how AI can extract features of atrial myopathy from routine cardiac CT to improve prediction of cardioembolic stroke.
🔹 OCT vs IVUS — ISOLEDS supports OCT as an alternative to IVUS for appropriately selected distal left-main bifurcation PCI, further strengthening the role of intravascular imaging in precision PCI.
🔹 Amyloid PET — early data with ¹²⁴I-evuzamitide PET point toward quantitative molecular imaging of cardiac amyloidosis and a future in which we increasingly image disease biology, not simply anatomy.
A personal highlight was participating in the
@escardio Paul Hugenholtz Lecture in Innovation, celebrating Professor Charalambos Antoniades and the transformative role of AI in cardiovascular imaging and medicine!
📌 My
#ESCCongress 2026 imaging take-home:
Echo → phenotype
CMR → tissue & etiology
CT → anatomy, physiology & plaque burden
IVUS/OCT → precision PCI
PET → molecular disease
AI → extracting more value from every image
The future of cardiovascular imaging is not simply about acquiring better pictures. It is about extracting more meaningful information from them and translating that information into better clinical decisions for our patients.
For the
#EACVI, our responsibility is to ensure these innovations are scientifically robust, clinically validated, reproducible and responsibly translated into everyday cardiovascular care.
Congratulations to our imaging community and to everyone contributing to this exciting transformation! ❤️
#ESCCongress #CVImaging #Echocardiography #CMR #CCTA #CardiacCT #NuclearCardiology #ArtificialIntelligence
@NAjmoneMarsan @RNijveldt @chiarabd @Cosyns @bogdan_popescu1 @denisamuraru @s_e_petersen @rmanka_ @AnnaGiuliaPavon @WilliamZoghbi @pattypellikka @HEARTinMagnet @rafavidalperez @Hragy @Sarah_Moharem @VictoriaDe32503